Gemcitabine Plus Vinorelbine as Second-line Chemotherapy of the Patients of Previously Treated Non-small Cell lung Cancer: Phase II Trial.
10.4046/trd.2005.58.4.344
- Author:
Pil Soon JANG
1
;
Hyun Mo KANG
;
Jeong Eun LEE
;
Seon Jung KWON
;
Jin Young AN
;
Yun Sun LEE
;
Sung Soo JEONG
;
Ju Ock KIM
;
Sun Young KIM
Author Information
1. Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute Daejeon, Korea. sykim@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Advanced non-small cell lung cancer;
Second-line chemotherapy;
Gemcitabine;
Vinorelbine
- MeSH:
Anemia;
Carcinoma, Non-Small-Cell Lung*;
Drug Therapy*;
Humans;
Neutropenia;
Survival Rate;
Thrombocytopenia
- From:Tuberculosis and Respiratory Diseases
2005;58(4):344-351
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. MATERIALS AND METHODS: 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine 25mg/m2 followed by an infusion of gemcitabine 1000mg/m2 on day 1 and day 8 every three weeks. This course was repeated more than twice. RESULTS: Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI 1-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. CONCLUSION: A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness.
